Immunocytokines with activity-on-demand by combination with small molecule inhibitors
Dose-limiting systemic toxicity constitutes a major impediment to the application of cytokines in cancer therapy. To enhance the therapeutic index, tumor-directed antibody-cytokine fusion proteins, i.e., immunocytokines, are developed for targeting-mediated cytokine enrichment at the tumor site, all...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2024-03-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.1038/s44321-024-00047-9 |